Chinook Therapeutics, Inc. Common Stock
KDNY
KDNY was delisted on the 10th of August, 2023.
102 hedge funds and large institutions have $138M invested in Chinook Therapeutics, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 42 increasing their positions, 20 reducing their positions, and 4 closing their positions.
9,033% more call options, than puts
Call options by funds: $274K | Put options by funds: $3K
425% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 4
110% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 20
45% more capital invested
Capital invested by funds: $95.6M → $138M (+$42.7M)
20% more funds holding
Funds holding: 85 → 102 (+17)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$6.76M |
| 2 |
Renaissance Technologies
New York
|
+$2.77M |
| 3 |
TA
Teachers Advisors
New York
|
+$2.06M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$1.91M |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$1.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$15.8M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$5.87M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.82M |
| 4 |
BlackRock
New York
|
-$1.11M |
| 5 |
Morgan Stanley
New York
|
-$895K |
KDNY Hedge Fund Activity: Q1 2019 in Review
102 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Chinook Therapeutics, Inc. Common Stock (KDNY) for Q1 2019, worth a combined $138M — up 45% from $95.6M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new KDNY positions and 4 closed out — a net gain of 17 holders — while 42 added to existing stakes and 20 trimmed.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $6.76M. The largest seller was Wellington Management Group, exiting entirely with an estimated $15.8M sold.
- 102 institutional investors held Chinook Therapeutics, Inc. Common Stock (KDNY) as of Q1 2019, up from 85 in Q4 2018.
- Funds reported $138M of Chinook Therapeutics, Inc. Common Stock stock for Q1 2019, up 45% quarter-over-quarter.
- 21 funds opened new Chinook Therapeutics, Inc. Common Stock positions in Q1 2019 and 4 closed out, a net change of +17 holders.
- The largest Chinook Therapeutics, Inc. Common Stock buyer in Q1 2019 was EcoR1 Capital, an estimated $6.76M added.
- The largest Chinook Therapeutics, Inc. Common Stock seller in Q1 2019 was Wellington Management Group, an estimated $15.8M sold.
Based on aggregated 13F filings for Q1 2019.